

Freedom of Information Request: Our Reference CTMUHB_331_20

Please note that the information provided below is data that is recorded centrally on our Medicines Management system, by medicine and by diagnosed eye condition.

Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

1. Within your Health Board how many intra-vitrear injections/implants of each of the following drugs have been used in the four-month period from May-August 2020:

Aflibercept - 1706
Bevacizumab - 42
Brolucizumab - 0
Dexamethasone - 49
Fluocinolone – Less than 5
Ranibizumab – 160

2. If your Health Board is able to identify intra-vitrear injections/implants by eye condition, please provide the number of injections/implants used from May-August 2020, for each of the following conditions:

Wet Age Related Macular Degeneration (wAMD)

Aflibercept - 1178
Bevacizumab – 0
Brolucizumab - 0
Dexamethasone – 0
Fluocinolone - 0
Ranibizumab - 104

Diabetic Macular Oedema (DMO)

Aflibercept - 284
Bevacizumab - 0
Dexamethasone (Chronic DMO) - 5
Fluocinolone - 0
Ranibizumab - 23

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

Aflibercept - 230

Bevacizumab - 0

Dexamethasone (DMO Secondary to RVO) - Less than 5

Fluocinolone - 0

Ranibizumab - 28

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

Aflibercept - 14

Bevacizumab - 0

Dexamethasone - 0

Fluocinolone - 0

Ranibizumab - 0

3. Within your Health Board how many patients have been treated for Uveitis in the four-month period from May to August 2020 with the following:

- Dexamethasone intra-vitreous implants - Less than 5
- Any other anti-VEGF injections/implants - 0
- Infliximab - 0
- Adalimumab - 0
- Tocilizumab - 0